在患有不安腿综合征的患者中,多巴胺激动剂反应的性别差异
Maria P Mogavero1,2, Elena Antelmi3,4, Giuseppe Lanza5,6
1Vita-Salute San Raffaele University, Milan, Italy.
Journal of sleep research
|August 19, 2024
概括
患有不安腿综合征 (RLS) 的女性在服用多巴胺激动剂后,在睡眠期间 (PLMS) 的周期性腿部运动中表现出更大的改善. 这表明了特定于性别的RLS治疗策略的潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 睡眠医学 睡眠医学
背景情况:
- 不安腿综合征 (RLS) 是一种神经疾病,其特点是迫切需要移动腿部,通常伴有不舒服的感觉.
- 在RLS流行率和症状严重程度上观察到与性别相关的差异,但治疗反应差异的理解较少.
- 多巴胺激动剂,如pramipexole和ropinirole,是RLS的常见治疗方法,旨在通过调节多巴胺基通路来缓解症状.
研究的目的:
- 研究患有不安腿综合征 (RLS) 的患者对多巴胺激动剂 (pramipexole和ropinirole) 的急性反应的潜在基于性别的差异.
- 分析临床和多睡眠学 (PSG) 参数,以确定导致RLS治疗疗效和睡眠质量性别差异的因素.
- 探索这些发现对制定性别特异性RLS治疗方法的影响.
主要方法:
- 一组由41名没有药物治疗的成年RLS患者组成的队列接受了两晚的多睡眠学 (PSG).
- 在第二次PSG之前,患者接受了pramipexole (0.25毫克) 或ropinirole (0.5毫克).
- 使用视觉模拟尺度 (VAS) 评估了PSG后的症状严重程度;PSG数据包括睡眠期间的腿部运动 (LMS) 和周期性LMS (PLMS).
主要成果:
- 女人表现出更高的基线睡眠效率和N2阶段睡眠,而男性在入睡后更清醒.
- 在治疗后,与男性相比,女性的总LMS,PLMS和周期性指数显著减少.
- 所有患者在治疗后报告了VAS得分的降低,在主观症状改善方面没有显著的性别差异.
结论:
- 与男性相比,患有RLS的女性在睡眠期间 (PLMS) 对多巴胺激动剂的周期性腿部运动的急性反应性更高.
- 女性的这种增强反应可能与多巴胺受体表达的性别特异性有关,特别是D3受体.
- 研究结果表明,针对RLS的量身定制的,性别特定的治疗策略,特别是针对PLMS的多巴胺激动剂治疗,可以改善患者的治疗结果.
更多相关视频
相关概念视频
Restless Leg Syndrome and Night Terrors
159
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
159
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
287
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
287
Parkinson's Disease: Treatment
240
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
240
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
230
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
230
REM Sleep Behavior Disorder
163
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
163
Antidepressant Drugs: MAOIs and Other Agents
209
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
209


